LivaNova PLC (LIVN)
| Market Cap | 4.39B +83.0% |
| Revenue (ttm) | 1.43B +12.4% |
| Net Income | 107.15M |
| EPS | 1.94 |
| Shares Out | 54.93M |
| PE Ratio | 41.15 |
| Forward PE | 18.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 748,176 |
| Open | 78.50 |
| Previous Close | 78.38 |
| Day's Range | 77.45 - 80.74 |
| 52-Week Range | 41.02 - 80.74 |
| Beta | 0.88 |
| Analysts | Buy |
| Price Target | 80.60 (+0.83%) |
| Earnings Date | May 6, 2026 |
About LIVN
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing sy... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for LIVN stock is "Buy." The 12-month stock price target is $80.6, which is an increase of 0.83% from the latest price.
News
Jette Nygaard-Andersen Joins LivaNova Board as a New Director
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company's Board of Directors a...
LivaNova Transcript: AGM 2026
The meeting was held virtually with strong shareholder participation and all quorum requirements met. Ten resolutions covering director elections, compensation, auditor appointments, and share repurchase were presented, with final results to be published. No shareholder questions were received.
LivaNova Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a strategy focused on core business reinvestment, expansion into high-growth markets, and disciplined capital allocation. Key wins include improved VNS reimbursement and manufacturing scale, while OSA and new product launches are set to drive future growth.
LivaNova appoints Liddy as Chief Legal Officer
LivaNova (LIVN) announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31. Liddy will oversee the Company’s global legal and compliance function and serve as a member…
LivaNova Appoints Anne Liddy as Chief Legal Officer
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the appointment of Anne Liddy as Chief Legal Officer, effective August...
LivaNova appoints Stefano Folli as President, Cardiopulmonary
ivaNova (LIVN) announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary effective June 1, succeeding Franco Poletti, who will retire on July 31. Folli will partner clo...
LivaNova appoints Franco Poletti as President, Cardiopulmonary
LivaNova (LIVN) announced that Stefano Folli will join the Company as incoming President, Cardiopulmonary effective June 1, succeeding Franco Poletti, who will retire on July 31. Folli will partner cl...
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Stefano Folli will join the Company as incoming Presid...
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Con...
LivaNova price target lowered to $76 from $78 at Baird
Baird lowered the firm’s price target on LivaNova (LIVN) to $76 from $78 and keeps an Outperform rating on the shares.The firm updated its model following beat and raise Q1…
LivaNova price target raised to $90 from $85 at Mizuho
Mizuho raised the firm’s price target on LivaNova (LIVN) to $90 from $85 and keeps an Outperform rating on the shares.
LivaNova price target raised to $76 from $73 at Barclays
Barclays raised the firm’s price target on LivaNova (LIVN) to $76 from $73 and keeps an Equal Weight rating on the shares.
LivaNova reports Q1 adjusted EPS 98c, consensus 90c
Reports Q1 revenue $362.3M, consensus $346.11M. “In the first quarter, LivaNova (LIVN) delivered double-digit revenue growth with strength across all regions, driven by sustained performance in our Ca...
LivaNova raises FY26 adjusted EPS view to $4.20-$4.30 from $4.15-$4.25
FY26 consensus $4.21. LivaNova (LIVN) now expects full-year 2026 revenue to grow between 7.0% and 8.0% (versus 6.0% and 7.0% prior) on a constant-currency basis. Foreign currency is expected to…
LivaNova Earnings Call Transcript: Q1 2026
Q1 2026 saw 11% revenue growth, driven by strong cardiopulmonary and epilepsy performance, with upgraded full-year guidance reflecting robust demand and key regulatory milestones in OSA. Adjusted EPS and revenue outlooks were raised, and capital investments continue to support expansion.
LivaNova Earnings release: Q1 2026
LivaNova released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
LivaNova Slides: Q1 2026
LivaNova has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
LivaNova Quarterly report: Q1 2026
LivaNova has published its Q1 2026 quarterly earnings report on May 6, 2026.
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year...
LivaNova Proxy statement: Proxy filing
LivaNova filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
LivaNova Proxy statement: Proxy filing
LivaNova filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article...
LivaNova to Announce First-Quarter 2026 Results
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, ...
LivaNova granted premarket approval for aura6000 System by FDA
LivaNova (LIVN) announced the FDA granted premarket approval for the aura6000 System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea. The System utilizes proximal h...
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted premarket approva...